Patents Assigned to Bayer Intellectual Property GmbH
  • Patent number: 10865406
    Abstract: The present invention relates to an ALS inhibitor herbicide tolerant Beta vulgaris plant and parts thereof comprising a mutation of an endogenous acetolactate synthase (ALS) gene, wherein the ALS gene encodes an ALS polypeptide containing an amino acid different from tryptophan at a position 569 of the ALS polypeptide.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: December 15, 2020
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, KWS SAAT AG
    Inventors: Ruediger Hain, Juergen Benting, Guenter Donn, Nathalie Knittel-Ottleben, Bernd Holtschulte, Andreas Loock, Clemens Springmann, Rudolf Jansen
  • Publication number: 20200385335
    Abstract: The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 10, 2020
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Michael Hahn, Thomas Lampe, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Friederike Stoll, Andreas Knorr, Elisabeth Woltering
  • Publication number: 20200377614
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte Christine KOPITZ, Joachim SCHUHMACHER
  • Patent number: 10781263
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 22, 2020
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
  • Patent number: 10751361
    Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: August 25, 2020
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Albert Abraham, Daniel Keil, Jason Nickell, Christian Weiss
  • Patent number: 10647779
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: May 12, 2020
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Kopitz, Joachim Schuhmacher
  • Patent number: 10604532
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: March 31, 2020
    Assignees: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion Hitchcock, Anne Mengel, Vera Pütter, Gerhard Siemeister, Antje Margret Wengner, Hans Briem, Knut Eis, Volker Schulze, Amaury Ernesto Fernandez-Montalvan, Stefan Prechtl, Simon Holton, Jörg Fanghänel, Philip Lienau, Cornelia Preusse, Mark Jean Gnoth
  • Patent number: 10548315
    Abstract: The present invention relates to the use of succinate dehydrogenase Inhibitors for extending shelf life and storage stability of fruits and vegetables, to a method for extending shelf life of fruits and vegetables by applying a succinate dehydrogenase inhibitor to the crops prior to the harvest of the fruits or vegetables and to a fruit or vegetable treated with a succinate dehydrogenase Inhibitor.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: February 4, 2020
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Heiko Rieck, Hélène Lachaise, Gilbert Labourdette, Pete Howard Davies, Dominique Steiger, Luk De Maeyer, George Hauley Musson, IV, Lorianne Fought, Sylvain Tafforeau
  • Patent number: 10544426
    Abstract: Present invention relates to the use of the ALS inhibitor herbicides for controlling unwanted vegetation in ALS inhibitor herbicide tolerant Beta vulgaris plants, more especially, present invention relates to the use of ALS inhibitor herbicides for control of unwanted vegetation in Beta vulgaris, preferably in sugar beet growing areas in which the Beta vulgaris, preferably sugar beet comprise a mutation in codon 1705-1707 of an endogenous ALS gene encoding an ALS protein containing an amino acid that is different from tryptophan at position 569, preferably the tryptophan is substituted by leucine.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: January 28, 2020
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ruediger Hain, Gerhard Johann, Guenter Donn
  • Patent number: 10487079
    Abstract: The invention relates to novel heteroaryl carboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 26, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Martin Hendrix, Frank-Gerhard Böß, Christina Erb, Joachim Krüger, Christoph Methfessel, Rudy Schreiber, Welf-Burkhard Wiese, Joachim Luithle
  • Patent number: 10463606
    Abstract: The invention is directed to the use of alternan as texturizing agent, particularly as fat or oil replacer in foodstuffs or cosmetic preparations, a homogeneous composition comprising alternan and water, the use of the homogeneous composition as texturizing agent in foodstuffs or cosmetic preparations, and foodstuffs and cosmetic preparations comprising alternan as texturizing agent or a homogeneous composition comprising alternan.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 5, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Claus Frohberg, Jens Pilling
  • Patent number: 10463666
    Abstract: The present invention relates to a pharmaceutical composition which comprises progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, can be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused by folate deficiency such as, for example, neural tube defects, ventricular valve defects, urogenital defects, and cleft lip, jaw and palate, without masking the symptoms of vitamin B12 deficiency, and at the same time even in the case of homozygous or heterozygous polymorphism of methylenetetrahydrofolate reductase facilitates unimpaired utilizability of the folate component 5-methyl-(6S)-tetrahydrofolate by the body and thus its biological activity for preventing the abovementioned congenital malformations caused by folate deficiency.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 5, 2019
    Assignees: MERCK & CIE, Bayer Intellectual Property GmbH
    Inventors: Kai Strothmann, Gavin Welch Wasserfall-Smith, Klaus Pietrzik, Kristina King, Rudolf Moser
  • Patent number: 10435417
    Abstract: A process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration is described. The process is carried out using specifically controlled crystallization conditions.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 8, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 10433550
    Abstract: The present invention relates to active compound combinations for reducing the damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, nematodes or phytopathogens and which have fungicidal or nematicidal or insecticidal activity including any combination of the three activities, in particular within a composition, which comprises (A) Fluopyram, (B) a spore-forming bacterium of the genera Bacillus, selected from Bacillus firmus, Bacillus cereus, Bacillus pumilis, Bacillus amyloliquefaciens, Bacillus subtilis strain GB03, Bacillus subtilis strain QST713, and (C) at least one biological control agent, in particular bacteria, fungi or yeasts, protozoa, viruses, entomopathogenic nematodes, inoculants, botanicals and products produced by microorganisms including proteins or secondary metabolites.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: October 8, 2019
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, BAYER CROPSCIENCE AG
    Inventors: Elke Hellwege, Heike Hungenberg
  • Patent number: 10435372
    Abstract: Compounds (A) can be used for increasing the yield of useful plants or crop plants with respect to their harvested plant organs, wherein the Compound (A) is selected from compounds of the formula (I) or salts thereof, in which (R1)n is n radicals R1 where the R1 are identical or different and are each halogen or (C1-C4)-haloalkyl, n is an integer from 1 to 3, R2 is hydrogen, (C1-C6)-alkyl, (C1-C4)-alkoxy-(C1-C4)-alkyl, (C3-C6)-cycloalkyl, tri-(C1-C4)-alkyl-silyl or tri-(C1-C4)-alkyl-silylmethyl, R3 is hydrogen, (C1-C6)-alkyl, (C1-C6)-haloalkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl or (C3-C6)-cycloalkyl, and R4 is hydrogen or (C1-C12)-alkyl, preferably mefepyr-diethyl (Compound (A1)]
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: October 8, 2019
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Erwin Hacker, Stefan Lehr, Georg Bonfig-Picard, Martin Hess, Frank Ziemer, Mathias Schmidt, Martin Jeffrey Hills, Udo Bickers, Juan Pedro Ruiz-Santaella Moreno
  • Patent number: 10426169
    Abstract: Heteroarylpiperidine and -piperazine derivatives of the formula (I) in which the symbols RA1, RA2, X, Y, L1, L2, RB1, RB2, G, Q, p, R1, R2 and R10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: October 1, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Tomoki Tsuchiya, Pierre Wasnaire, Sebastian Hoffmann, Thomas Seitz, Stefan Hillebrand, Juergen Benting, Jan Peter Schmidt, Pierre Cristau
  • Publication number: 20190284206
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 19, 2019
    Applicants: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
  • Patent number: 10414762
    Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: September 17, 2019
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Joachim Luithle, Frank-Gerhard Böβ, Christina Erb, Katrin Schnizler, Timo Flessner, Marja van Kampen, Christoph Methfessel
  • Patent number: 10383876
    Abstract: The present invention relates:—to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;—to methods of preparing said dihydrochloride salt;—to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;—to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;—to a pharmaceutical composition comprising said dihydrochloride salt; and—to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agent
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: August 20, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Jan-Georg Peters, Hans-Christian Militzer, Hartwig Müller
  • Patent number: 10383877
    Abstract: The present invention relates to the use of 2,3-dihydroimidazo[1,2-c]quinazoline compounds, and of pharmaceutical compositions containing such compounds, for the treatment or prophylaxis of multiple myeloma, as a sole agent or in combination with other one or more other active ingredients.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: August 20, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventor: Ningshu Liu